LIGAND PHARMACEUTICALS INCORPORATED Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
LIGAND PHARMACEUTICALS INCORPORATED (LGNZZ) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $10.60 million as of 2016-03-31, per its 10-Q filed 2016-11-14.
Discontinued › Notes › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2016-11-14
- 2016-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $10.60M.
- 2015-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.40M.
- 2015-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.40M.
- 2015-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.40M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2016-03-31 | $10.60M 10-Q · filed 2016-11-14 |
| 2015-09-30 | $2.40M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $2.40M 10-Q · filed 2015-08-05 |
| 2015-03-31 | $2.40M 10-Q · filed 2015-05-11 |
| 2014-09-30 | $2.40M 10-Q · filed 2014-10-31 |
| 2014-06-30 | $2.40M 10-Q · filed 2014-08-05 |
| 2014-03-31 | $2.40M 10-Q · filed 2014-05-07 |
| 2013-09-30 | $2.40M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $2.40M 10-Q · filed 2013-08-01 |
| 2013-03-31 | $2.40M 10-Q · filed 2013-05-08 |